Company Overview of Famy Care Ltd.
Famy Care Ltd. manufactures and supplies hormonal and reproductive health care products. It offers oral and emergency contraceptives, intra uterine devices, tubal ligation rings, progestagen only pills, hormonal tablets, and cancer detection kits. Famy Care Ltd. was founded in 1987 and is based in Mumbai, India.
12/14, Veer Nariman Road
Mumbai, 400 001
Founded in 1987
Key Executives for Famy Care Ltd.
Famy Care Ltd. does not have any Key Executives recorded.
Famy Care Ltd. Key Developments
Warner Chilcott plc Enters into Settlement and License Agreement with Mylan Inc. and Mylan Pharmaceuticals Inc. and Famy Care Ltd
Jul 29 13
Warner Chilcott plc has entered into a settlement and license agreement with Mylan Inc. and Mylan Pharmaceuticals Inc. (together, Mylan') and Famy Care Ltd. (Famy Care") to resolve patent litigation related to the company's U.S. Patent No. 5,552,394 (the '394 Patent"), which covers LOESTRIN 24 FE and expires July 22, 2014. Pursuant to the agreement, Mylan and Famy Care have agreed, among other things, not to commence marketing their generic equivalent LOESTRIN 24 FE product until the earlier of July 1, 2014 or the date on which a third party (other than pursuant to the company's January 2009 settlement and license agreement) enters the market with a generic version of LOESTRIN 24 FE in the United States with or without authorization from the company. Pursuant to the agreement, the company's pending '394 Patent litigation with Mylan and Famy Care will be dismissed. The agreement is required to be submitted to, and is subject to the review of, the U.S. Department of Justice and the Federal Trade Commission. The Company had previously received a Paragraph IV certification notice letter from Mylan, as U.S. agent for Famy Care, indicating that Famy Care had submitted to the U.S. Food and Drug Administration an Abbreviated New Drug Application seeking approval to manufacture and sell a generic version of LOESTRIN 24 FE. The company subsequently filed a lawsuit against Famy Care and Mylan in the U.S. District Court for the District of New Jersey charging each with infringement of the '394 Patent.
Mylan, Inc. Announces Ortho Tri-Cyclen Lo(R) Settlement Agreement with Janssen Pharmaceuticals, Inc
Nov 8 12
Mylan, Inc. announced that it, along with Famy Care Ltd., has entered into a settlement agreement with Janssen Pharmaceuticals, Inc. that will resolve patent litigation related to Norgestimate/Ethinyl Estradiol Tablets 0.180 mg/0.025 mg, 0.215 mg/0.025 mg and 0.250 mg/0.025 mg. Norgestimate/Ethinyl Estradiol Tablets are the generic version of Janssen Pharmaceuticals Inc.'s Ortho Tri-Cyclen Lo(R) Tablets, which are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. According to the terms of the settlement, Mylan will be licensed to sell its Norgestimate/Ethinyl Estradiol Tablets 0.180 mg/0.025 mg, 0.215 mg/0.025 mg and 0.250 mg/0.025 mg, on December 31, 2015, or earlier under certain circumstances. Pursuant to the agreement, pending litigation will be dismissed. All other terms and conditions of the settlement are confidential, and the agreement itself is subject to review by the U.S. Department of Justice and the Federal Trade Commission.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|